Company intelligence / Profile preview

3io Therapeutics

Toronto, Ontario, Canadaca.linkedin.com ↗

Ownership: Private
Development stage: Preclinical

Overview

3io Therapeutics is developing an innovative oncolytic viral immunotherapy targeting KRAS-mutant lung, colorectal and pancreatic cancers. The approach leverages a non-pathogenic virus to activate immune responses against tumors and metastases. The company has partnered with McMaster University to advance this technology. As of now, there are no reported clinical trial results.

Therapeutic areas: Oncology
Modalities: Oncolytic virus therapy
Industry: Biotech

Drug pipeline

1 asset

BHV-1

Preclinical

Partnerships

McMaster University

Beyond the preview

Go deeper on 3io Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 3io Therapeutics.

Explore the full profile